IPP Bureau
USFDA approves first treatment option for generalized pustular psoriasis flares in adults
By IPP Bureau - September 03, 2022
Spesolimab is a monoclonal antibody that inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for the treatment of generalized pustular psoriasis flares
Ashland to expand bioresorbable polymers capacity in Ireland
By IPP Bureau - September 02, 2022
The capital expansion program commenced in June 2022 and is expected to complete in 2024
Centre grants approval of three Bulk Drug Parks
By IPP Bureau - September 02, 2022
The Bulk Drug Parks to be developed under the scheme will provide common infrastructure facilities at one place thereby creating a robust ecosystem for the bulk drug manufacturing in the country and also reducing manufacturing cost significantly
Infosys completes acquisition of BASE life science
By IPP Bureau - September 02, 2022
The acquisition reaffirms Infosys’ commitment to help global life sciences companies
NATCO Pharma to sell stake in Nativita and assets of Pharma division
By IPP Bureau - September 02, 2022
NATCO to sell 15% of shareholding in Nativita for euro 3,45,000 to Pharmasyntez-Nord
Kimia Biosciences unveils new logo, new website
By IPP Bureau - September 02, 2022
USFDA inspection at Alembic Pharmaceuticals Injectable Facility (F-3) at Karkhadi
By IPP Bureau - September 02, 2022
Zydus receives final approval from USFDA for two tablets
By IPP Bureau - September 01, 2022
The group now has 322 approvals and has so far filed over 428 ANDAs since the commencement of the filing process in FY 2003-04
US FDA issues 17 observations for Biocon Biologics sites
By IPP Bureau - September 01, 2022
The observations primarily relate to the need for improving strategies for microbial control, enhancing quality oversight, augmenting the use of software applications & computerized tools
Stelis Biopharma’s flagship facility receives EIR from USFDA
By IPP Bureau - September 01, 2022
The integrated capabilities at Unit 2 offer significant operational flexibility, greater efficiency, and varied scope within the same premise
Bayer showcases cancer study data at ESMO Congress 2022
By IPP Bureau - September 01, 2022
On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors
A 10-year commission with dedicated mission is required to tackle the upsurge of diabetes in India: says Expert
By IPP Bureau - September 01, 2022
India is at the forefront of research in cardiology worldwide but making indigenous products is what we are lacking & it needs to be improved
Bayer initiates Phase III study program to investigate oral FXIa inhibitor asundexian
By IPP Bureau - September 01, 2022
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke
Hydration of proteins could act as a potential marker for an early detection of neuro-degenerative diseases
By IPP Bureau - September 01, 2022
This dense phase often resembles liquid droplets exhibiting higher protein density and weaker molecular motion than the surrounding medium.
Medix Biochemica appoints former Roche executive to its Board of Directors
By IPP Bureau - September 01, 2022
Dr. Pedrocchi is currently an Independent Strategic Advisor and Non-Executive Director to private and public healthcare companies.
